5
Participants
Start Date
July 1, 2021
Primary Completion Date
October 31, 2023
Study Completion Date
October 31, 2025
TAA05 cell injection
"Chimeric antigen receptor T cells (car-t)~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner,which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
RECRUITING
Anhui Provincial Hospital, Hefei
Lead Sponsor
Anhui Provincial Hospital
OTHER_GOV
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
INDUSTRY